• Trelagliptin Succinate: Applied Workflows in Diabetes Resear

  2026-07-09

  Trelagliptin succinate (SYR-472 succinate) empowers translational diabetes and metabolic research with its potent, selective DPP-4 inhibition and proven once-weekly activity. Discover actionable protocols, troubleshooting tactics, and innovative cross-disciplinary applications that set it apart from other DPP-4 inhibitors.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Techn

  2026-07-08

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) addresses the challenge of protein degradation during extraction, especially in workflows where EDTA is incompatible. It is suitable for Western blotting, co-IP, kinase assays, and other protease-sensitive protocols. Avoid use where DMSO disrupts cell or protein integrity or where protease inhibition is unnecessary.

• ARCA Cy3 EGFP mRNA (5-moUTP): Deep Dive Into Mechanisms & As

  2026-07-08

  Explore the scientific mechanisms and translational assay design considerations underlying ARCA Cy3 EGFP mRNA (5-moUTP), a 5-methoxyuridine modified mRNA. Gain unique insights beyond workflow guides, focusing on molecular engineering, immune suppression, and emerging delivery innovations.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-07-07

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for precise modulation of PI3K/AKT and histone acetylation pathways in established cancer cell models. It is optimized for in vitro workflows requiring controlled cell cycle arrest and apoptosis assessment, but should not be used for diagnostic or therapeutic purposes.

• A20 Modulates Oxidized Self-DNA-Driven Inflammation in AKI

  2026-07-07

  This study elucidates how the ubiquitin-editing enzyme A20 mitigates oxidized self-DNA-induced inflammation in acute kidney injury (AKI) by interfering with the NLRP3 inflammasome pathway. The findings reveal a distinct mechanism for controlling sterile inflammation in AKI, opening new translational avenues for inflammasome-targeted therapies.

• Demethyleneberberine (N2087): Reliable Cell Assays & Pathway

  2026-07-06

  This article offers a scenario-driven, evidence-based guide for biomedical researchers and technicians considering Demethyleneberberine (SKU N2087) in cell viability, proliferation, and cytotoxicity assays. It addresses experimental pitfalls, data reproducibility, and protocol optimization, drawing on robust literature and performance data to position Demethyleneberberine as a trusted solution for pathway-targeted workflows.

• Tacrine Hydrochloride Hydrate: Scaffold for Next-Gen Alzheim

  2026-07-06

  Explore the advanced use of Tacrine hydrochloride hydrate in Alzheimer’s disease research. This article uncovers its role as a molecular scaffold for multi-target drug development and offers unique assay insights for neurodegenerative disease models.

• Phosphatase Inhibitor Cocktail 2: Safeguarding Proteostasis

  2026-07-05

  Explore how Phosphatase Inhibitor Cocktail 2 enables precise protein phosphorylation preservation in aging and neurodegeneration studies. This article uniquely unpacks SIRT6-driven proteostasis loss, offering actionable insight for signaling research.

• Cimetidine (SKU B1557): Reliable Solutions for Cell-Based As

  2026-07-04

  Discover how Cimetidine (SKU B1557), a histamine-2 receptor antagonist with a unique pharmacological profile, addresses real-world reproducibility and compatibility challenges in cell viability, proliferation, and cytotoxicity assays. Drawing from validated protocols and recent literature, this article provides evidence-based, scenario-driven guidance for biomedical researchers, highlighting Cimetidine’s solubility, purity, and application in advanced laboratory workflows.

• Exendin-4 (Exenatide): Applied Workflows for Diabetes Resear

  2026-07-03

  Exendin-4 (Exenatide) is transforming type 2 diabetes and beta cell research with robust insulin-sensitizing effects, validated in both in vitro and in vivo models. This article details best-practice workflows, common pitfalls, and the latest advances in affordable production, equipping scientists to optimize experimental outcomes with confidence.

• Berberine Hydrochloride: Protocols and Innovations in Metabo

  2026-07-03

  Unlock reproducible metabolic and inflammation assays with Berberine Hydrochloride, leveraging its unique AMPK activation and ferroptosis inhibition. Discover protocol optimizations, troubleshooting strategies, and cross-domain insights informed by the latest advances in inflammasome research.

• High-Throughput BBB Permeability Prediction Using Surrogate

  2026-07-02

  Hu et al. developed an in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells with lysosomal trapping correction, achieving robust, high-throughput prediction of CNS drug permeability. This approach enables more accurate early-stage screening for brain-penetrant compounds, reducing reliance on in vivo studies and accelerating CNS drug development.

• Precision Targeting of Na+/H+ Exchangers in Translational Re

  2026-07-02

  This thought-leadership article explores how 5-(N,N-dimethyl)-Amiloride (hydrochloride), a selective Na+/H+ exchanger inhibitor from APExBIO, is redefining intracellular pH regulation, cardiac contractile dysfunction research, and endothelial injury workflows. By bridging mechanistic insight with strategic guidance, we outline best practices and emerging opportunities for translational scientists working at the intersection of ion transport, sepsis biomarkers, and ischemia-reperfusion injury. The article integrates critical findings from recent research on endothelial biomarkers, contextualizes DMA’s experimental advantages, and delivers actionable protocol recommendations to optimize reproducibility and impact.

• Ertugliflozin (PF-04971729): Robust SGLT2 Inhibitor for Assa

  2026-07-01

  This article guides biomedical researchers through laboratory scenarios in diabetes mellitus research, highlighting how Ertugliflozin (PF-04971729), SKU A3715, addresses real assay challenges. Evidence-driven Q&A blocks demonstrate reliable glucose reabsorption inhibition, protocol optimization, and data interpretation using this selective SGLT2 inhibitor.

• Sitagliptin Phosphate Monohydrate: Reliable DPP-4 Inhibition

  2026-07-01

  This article provides scenario-driven, evidence-based guidance for biomedical researchers using Sitagliptin phosphate monohydrate (SKU A4036) in cell viability, proliferation, and cytotoxicity assays. Drawing from recent literature and practical lab experience, it demonstrates how this DPP-4 inhibitor enhances reproducibility and workflow efficiency in metabolic and incretin hormone research.

8125 records 7/542 page Previous Next First page 上5页 678910 下5页 Last page